TIGIT double-edited tumor-infiltrating lymphocytes

TIGIT double-edited tumor-infiltrating lymphocytes (TILs) represent a next-generation autologous cell therapy designed to treat advanced solid tumors. This approach involves harvesting TILs from a patient's tumor and using gene-editing technology, such as TALEN (Transcription Activator-Like Effector Nuclease), to knock out the expression of two key immune checkpoint receptors: TIGIT (T-cell immunoreceptor with Ig and ITIM domains) and PD-1 (Programmed Cell Death Protein 1). By permanently removing these inhibitory "brakes" directly from the therapeutic cells, the therapy aims to enhance the anti-tumor potency, metabolic fitness, and persistence of the lymphocytes within the immunosuppressive tumor microenvironment. The lead candidate in this category, IOV-5001, was developed by Iovance Biotherapeutics in collaboration with Cellectis. This dual-editing strategy is intended to provide a more robust immune response compared to traditional TIL therapies and may potentially reduce the need for systemic co-administration of checkpoint inhibitor antibodies.

Other names

TIGIT double-edited tumor-infiltrating lymphocytesPD-1/TIGIT double-edited TILPD-1/TIGIT KO TILIOV-5001IOV5001IOV 5001